Molecular modeling study on resistance of WT/D473H SMO to antagonists LDE-225 and LEQ-506

Pharmacological Research

Volumn 129, Issue , 2018, Pages 491-499

  Tu, Jing ^a   Li, Jiao Jiao ^a   Song, Li Ting ^a   Zhai, Hong Lin ^a   Wang, Juan ^a   Zhang, Xiao Yun ^a  

^a LANZHOU UNIVERSITY   (China)

Author keywords

Binding mechanism; Drug resistance; Molecular dynamics; Smoothened receptor

Indexed keywords

ANTINEOPLASTIC AGENT; LEQ 506; SMOOTHENED PROTEIN; SONIDEGIB; UNCLASSIFIED DRUG; BIPHENYL DERIVATIVE; LIGAND; PYRIDINE DERIVATIVE; SMO PROTEIN, HUMAN;

ARTICLE; CALCULATION; CONFORMATIONAL TRANSITION; DRUG BINDING; DRUG DECOMPOSITION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESISTANCE; DRUG STRUCTURE; ENERGY TRANSFER; HYDROGEN BOND; IC50; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MOLECULAR MODEL; MUTANT; MUTATION; PRIORITY JOURNAL; WILD TYPE; ANTAGONISTS AND INHIBITORS; GENETICS; HUMAN; METABOLISM;

BIPHENYL COMPOUNDS; DRUG RESISTANCE; HUMANS; LIGANDS; MODELS, MOLECULAR; MUTATION; PYRIDINES; SMOOTHENED RECEPTOR;

EID: 85035245035     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2017.11.025     Document Type: Article

References (43)

1. Zalewska, M., Siara, M., Sajewicz, W., G protein-coupledreceptors: abnormalities in signal transmission, disease states and pharmacotberapy. Acta Pol. Pharm. 71:2 (2014), 229–243.
2. Ferguson, S.S.G., Barak, L.S., Zhang, J., Caron, M.G., G-protein-coupled receptor regulation: role of G-protein-coupled receptor kinases and arrestins. Can. J. Physiol. Pharmacol. 74:10 (1996), 1095–1110.
3. Conn, P.J., Physiological roles and therapeutic potential of metabotropic glutamate receptors. Ann. N. Y. Acad. Sci. 1 (2003), 12–21.
4. Premont, R.T., Gainetdinov, R.R., Physiological roles of G protein-coupled receptor kinases and arrestins. Annu. Rev. Physiol., 2007, 511–534.
5. Wise, A., Gearing, K., Rees, S., Target validation of G-protein coupled receptors. Drug Discov. Today 7:4 (2002), 235–246.
6. Cooke, R.M., Brown, A.J.H., Marshall, F.H., Mason, J.S., Structures of G protein-coupled receptors reveal new opportunities for drug discovery. Drug Discov. Today 20:11 (2015), 1355–1364.
7. Overington, J.P., Al-Lazikani, B., Hopkins, A.L., Opinion − How many drug targets are there?, Nat. Rev. Drug Discov. 5:12 (2006), 993–996.
8. Drews, J., Drug discovery: a historical perspective. Science 287:5460 (2000), 1960–1964.
9. Palczewski, K., Kumasaka, T., Hori, T., Behnke, C.A., Motoshima, H., Fox, B.A., Le Trong, I., Teller, D.C., Okada, T., Stenkamp, R.E., Yamamoto, M., Miyano, M., Crystal structure of rhodopsin: a G protein-coupled receptor. Science 289:5480 (2000), 739–745.
10. Jacoby, E., Bouhelal, R., Gerspacher, M., Seuwen, K., The 7 TM G-protein-coupled receptor target family. ChemMedChem 1:8 (2006), 761–782.
11. Topiol, S., Sabio, M., The role of experimental and computational structural approaches in 7TM drug discovery. Expert Opin. Drug Discov. 10:10 (2015), 1071–1084.
12. Mason, J.S., Bortolato, A., Congreve, M., Marshall, F.H., New insights from structural biology into the druggability of G protein-coupled receptors. Trends Pharmacol. Sci. 33:5 (2012), 249–260.
13. A. Heifetz, G.F.X. Schertler, R. Seifert, C.G. Tate, P.M. Sexton, V.V. Gurevich, D. Fourmy, V. Cherezov, F.H. Marshall, R.I. Storer, I. Moraes, I.G. Tikhonova, C.S. Tautermann, P. Hunt, T. Ceska, S. Hodgson, M.J. Bodkin, S. Singh, R.J. Law, P.C. Biggin, 2015. GPCR structure, function, drug discovery and crystallography: report from Academia-Industry International Conference (UK Royal Society) Chicheley Hall, 1-2 September 2014, Naunyn-Schmiedebergs Arch. Pharmacol. 388(8), 883–903.
14. Ruat, M., Hoch, L., Faure, H., Rognan, D., Structure of the Smoothened receptor. Med. Sci. 29:10 (2013), 855–860.
15. Wang, C., Wu, H.X., Katritch, V., Han, G.W., Huang, X.P., Liu, W., Siu, F.Y., Roth, B.L., Cherezov, V., Stevens, R.C., Structure of the human smoothened receptor bound to an antitumour agent. Nature 497:7449 (2013), 338–343.
16. Ingham, P.W., McMahon, A.P., Hedgehog signaling in animal development: paradigms and principles. Genes Dev. 15:23 (2001), 3059–3087.
17. Lum, L., Beachy, P.A., The hedgehog response network: sensors, switches, and routers. Science 304:5678 (2004), 1755–1759.
18. Tang, J.Y., Mackay-Wiggan, J.M., Aszterbaum, M., Yauch, R.L., Lindgren, J., Chang, K., Coppola, C., Chanana, A.M., Marji, J., Bickers, D.R., Epstein, E.H., Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N. Engl. J. Med. 366:23 (2012), 2180–2188.
19. Rudin, C.M., Hann, C.L., Laterra, J., Yauch, R.L., Callahan, C.A., Fu, L., Holcomb, T., Stinson, J., Gould, S.E., Coleman, B., LoRusso, P.M., Von Hoff, D.D., de Sauvage, F.J., Low, J.A., Brief report: treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N. Engl. J. Med. 361:12 (2009), 1173–1178.
20. Ailles, L., Siu, L.L., Targeting the hedgehog pathway in cancer: can the spines be smoothened?. Clin. Cancer Res. 17:8 (2011), 2071–2073.
21. Peukert, S., Miller-Moslin, K., Small-molecule inhibitors of the hedgehog signaling pathway as cancer therapeutics. ChemMedChem 5:4 (2010), 500–512.
22. Sandhiya, S., Melvin, G., Kumar, S.S., Dkhar, S.A., The dawn of hedgehog inhibitors: vismodegib. J. Pharmacol. Pharmacother. 4:1 (2013), 4–7.
23. Yauch, R.L., Dijkgraaf, G.J.P., Alicke, B., Januario, T., Ahn, C.P., Holcomb, T., Pujara, K., Stinson, J., Callahan, C.A., Tang, T., Bazan, J.F., Kan, Z., Seshagiri, S., Hann, C.L., Gould, S.E., Low, J.A., Rudin, C.M., de Sauvage, F.J., Smoothened mutation confers resistance to a hedgehog pathway inhibitor in medulloblastoma. Science 326:5952 (2009), 572–574.
24. Skvara, H., Kalthoff, F., Meingassner, J.G., Wolff-Winiski, B., Aschauer, H., Kelleher, J.F., Wu, X., Pan, S., Mickel, L., Schuster, C., Stary, G., Jalili, A., David, O.J., Emotte, C., Antunes, A.M.C., Rose, K., Decker, J., Carlson, I., Gardner, H., Stuetz, A., Bertolino, A.P., Stingl, G., De Rie, M.A., Topical treatment of basal cell carcinomas in nevoid basal cell carcinoma syndrome with a smoothened inhibitor. J. Invest. Dermatol. 131:8 (2011), 1735–1744.
25. Peukert, S., He, F., Dai, M., Zhang, R., Sun, Y., Miller-Moslin, K., McEwan, M., Lagu, B., Wang, K., Yusuff, N., Bourret, A., Ramamurthy, A., Maniara, W., Amaral, A., Vattay, A., Wang, A., Guo, R., Yuan, J., Green, J., Williams, J., Buonamici, S., Kelleher, J.F. III, Dorsch, M., Discovery of NVP-LEQ506, a second-generation inhibitor of smoothened. Chemmedchem 8:8 (2013), 1261–1265.
26. Ohashi, T., Oguro, Y., Tanaka, T., Shiokawa, Z., Tanaka, Y., Shibata, S., Sato, Y., Yamakawa, H., Hattori, H., Yamamoto, Y., Kondo, S., Miyamoto, M., Nishihara, M., Ishimura, Y., Tojo, H., Baba, A., Sasaki, S., Discovery of the investigational drug TAK-441, a pyrrolo 3,2-c pyridine derivative, as a highly potent and orally active hedgehog signaling inhibitor: modification of the core skeleton for improved solubility. Bioorg. Med. Chem. 20:18 (2012), 5507–5517.
27. Lauressergues, E., Heusler, P., Lestienne, F., Troulier, D., Rauly-Lestienne, I., Tourette, A., Ailhaud, M.-C., Cathala, C., Tardif, S., Denais-Lalieve, D., Calmettes, M.-T., Degryse, A.-D., Dumoulin, A., De Vries, L., Cussac, D., Pharmacological evaluation of a series of smoothened antagonists in signaling pathways and after topical application in a depilated mouse model. Pharmacol. Res. Perspect., 4(2), 2016, e00214.
28. Schrödinger, Version 9.0. 2009, Schrödinger, LLC, New York, NY.
29. Frisch, M., Trucks, G., Schlegel, H., Scuseria, G., Robb, M., Montgomery, J. Jr, Vreven, T., Kudin, K., Burant, J., Gaussian 09, Revision A. 02. 2009, Gaussian, Inc, Wallingford CT.
30. Jo, S., Kim, T., Im, W., Automated builder and database of protein/membrane complexes for molecular dynamics simulations. PLoS One, 2(9), 2007, e880.
31. Woolf, T.B., Roux, B., Structure, energetics, and dynamics of lipid-protein interactions: a molecular dynamics study of the gramicidin A channel in a DMPC bilayer. Proteins 24:1 (1996), 92–114.
32. Lomize, M.A., Lomize, A.L., Pogozheva, I.D., Mosberg, H.I., OPM: Orientations of proteins in membranes database. Bioinformatics 22:5 (2006), 623–625.
33. Case, D., Babin, V., Berryman, J., Amber 14. 2014, University of California, San Francisco.
34. Wang, J.M., Wolf, R.M., Caldwell, J.W., Kollman, P.A., Case, D.A., Development and testing of a general amber force field. J. Comput. Chem. 25:9 (2004), 1157–1174.
35. Fox, T., Kollman, P.A., Application of the RESP methodology in the parametrization of organic solvents. J. Phys. Chem. B 102:41 (1998), 8070–8079.
36. Hornak, V., Abel, R., Okur, A., Strockbine, B., Roitberg, A., Simmerling, C., Comparison of multiple amber force fields and development of improved protein backbone parameters. Proteins 65:3 (2006), 712–725.
37. Dickson, C.J., Madej, B.D., Skjevik, A.A., Betz, R.M., Teigen, K., Gould, I.R., Walker, R.C., Lipid14: the amber lipid force field. J. Chem. Theory Comput. 10:2 (2014), 865–879.
38. Darden, T., York, D., Pedersen, L., Particle mesh ewald: an N [center-dot] log (N) method for ewald sums in large systems. J. Chem. Phys. 98:12 (1993), 10089–10092.
39. Ryckaert, J.P., Ciccotti, G., Berendsen, H.J.C., Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. J. Comput. Phys. 23:3 (1977), 327–341.
40. Li, J.J., Cheng, P., Tu, J., Zhai, H.L., Zhang, X.Y., Enhancing specificity in the Janus kinases: a study on the thienopyridine JAK2 selective mechanism combined molecular dynamics simulation. Mol. Biosyst. 12:2 (2016), 575–587.
41. Li, J.J., Tu, J., Cheng, P., Zhai, H.L., Zhang, X.Y., Insights into DFG-in and DFG-out JAK2 binding modes for a rational strategy of type II inhibitors combined computational study. RSC Adv. 6:51 (2016), 45540–45552.
42. Lauressergues, E., Heusler, P., Lestienne, F., Troulier, D., Rauly‐Lestienne, I., Tourette, A., Ailhaud, M.C., Cathala, C., Tardif, S., Denais‐Laliève, D., Pharmacological evaluation of a series of smoothened antagonists in signaling pathways and after topical application in a depilated mouse model. Pharmacol. Res. Perspect., 4(2), 2016 (n/a-n/a).
43. Le Guilloux, V., Schmidtke, P., Tuffery, P., Fpocket An open source platform for ligand pocket detection. BMC Bioinf., 10(168), 2009.